Li Shu, Wang Xiaotong, Li Qiuhong, Li Chunli
Department of Clinical Laboratory, Women and Children's Hospital of Chongqing Medical University, Chongqing 401174, P.R. China.
Department of Clinical Laboratory, Chongqing Health Center for Women and Children, Chongqing 401174, P.R. China.
Oncol Lett. 2022 Nov 22;25(1):19. doi: 10.3892/ol.2022.13605. eCollection 2023 Jan.
Src homology-2 domain-containing protein tyrosine phosphatase (SHP2)/PTP non-receptor type 11 (PTPN11) have been reported to be expressed in a variety of solid tumors, though its role in tumors remains controversial. The aim of the present study was to explore the role of SHP2/PTPN11 in the occurrence and prognosis of cancer. Literature on the relationship between SHP2/PTPN11 expression and tumor was searched in PubMed, China National Knowledge Infrastructure and Cochrane Library electronic database, following which the Stata 12.0 software was used for meta-analysis. A total of 23 articles were included in the present statistical analysis. Higher expression levels of SHP2/PTPN11 can significantly increase the risk of non-small-cell lung cancer [NSCLC; odds ratio (OR)=3.41, 95% confidence interval (CI)=1.07-10.80; P=0.037] while reducing the overall survival (OS) time of patients with NSCLC [hazards ratio (HR)=2.83, 95% CI=1.97-4.07; P<0.001]. In addition, increased expression of SHP2/PTPN11 can significantly increase the risk of gastric (OR=5.35, 95% CI=1.81-15.77; P=0.002) and cervical cancer (OR=12.04, 95% CI=3.45-42.01; P<0.001). However, no significant difference could be found in the expression level of SHP2/PTPN11 in liver cancer (OR=1.47, 95% CI=0.37-5.84; P=0.582) compared with that in the adjacent normal tissues. Taken together, SHP2/PTPN11 was found to be expressed highly in a number of tumors, which was in turn associated with tumorigenesis and patient prognosis. In particular, increased expression of SHP2/PTPN11 can increase the risk of NSCLC, gastric cancer and cervical cancer, whereas higher expression levels of SHP2/PTPN11 can reduce OS of NSCLC.
含Src同源2结构域的蛋白酪氨酸磷酸酶（SHP2）/非受体型蛋白酪氨酸磷酸酶11（PTPN11）已被报道在多种实体瘤中表达，但其在肿瘤中的作用仍存在争议。本研究的目的是探讨SHP2/PTPN11在癌症发生和预后中的作用。在PubMed、中国知网和考克兰图书馆电子数据库中检索关于SHP2/PTPN11表达与肿瘤关系的文献，随后使用Stata 12.0软件进行荟萃分析。本统计分析共纳入23篇文章。SHP2/PTPN11表达水平升高可显著增加非小细胞肺癌的风险[比值比（OR）=3.41，95%置信区间（CI）=1.07 - 10.80；P = 0.037]，同时缩短非小细胞肺癌患者的总生存期（OS）[风险比（HR）=2.83，95% CI = 1.97 - 4.07；P < 0.001]。此外，SHP2/PTPN11表达增加可显著增加胃癌（OR = 5.35，95% CI = 1.81 - 15.77；P = 0.002）和宫颈癌（OR = 12.04，95% CI = 3.45 - 42.01；P < 0.001）的风险。然而，与癌旁正常组织相比，肝癌中SHP2/PTPN11的表达水平无显著差异（OR = 1.47，95% CI = 0.37 - 5.84；P = 0.582）。综上所述，发现SHP2/PTPN11在多种肿瘤中高表达，这与肿瘤发生和患者预后相关。特别是，SHP2/PTPN11表达增加可增加非小细胞肺癌、胃癌和宫颈癌的风险，而SHP2/PTPN11较高的表达水平可缩短非小细胞肺癌患者的总生存期。
Zotero 插件
